Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BCL2 expression + MYC expression
i
Other names:
MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog, BCL2, Bcl-2, PPP1R50, B-cell CLL/lymphoma 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4609
;
596
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
BCL2/BCL2L1 ratio elevation (3)
BCL2 rearrangement + MYC amplification (2)
HR positive + MYC amplification (2)
MYC amplification + ALK F1174L (2)
MYC expression + MYC rearrangement (2)
MYC overexpression + IDH1 mutation (2)
MYC overexpression + IDH2 mutation (2)
MYC rearrangement + LDH elevation (2)
BCL2/MCL1 ratio elevation (2)
ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)
ALK positive + MYC amplification + CCND1 deletion (1)
EGFR T790M + MYC amplification (1)
HER-2 positive + MYC amplification (1)
HR positive + MYC mutation (1)
IDH1 mutation + MYC amplification + MAPRE1 overexpression (1)
IDH2 mutation + MYC amplification + MAPRE1 overexpression (1)
KIF5B-RET fusion + TP53 H193R + MYC amplification (1)
MYC amplification + BCL2 amplification + TNFRSF8 expression (1)
MYC mutation + ER positive (1)
miR-17-HG deletion + MYC positive (1)
BCL2 elevation + IGH elevation (1)
BCL2 fusion + EZH2 mutation (1)
Chr t(11;14) + BCL2 : BCL2L1 ratio elevation (1)
Chr t(11;14) + BCL2 overexpression (1)
PTEN deletion + BCL2 translocation (1)
BCL2/BAX ratio elevation (0)
BCL2/BCL2L1 ratio elevation (3)
BCL2 rearrangement + MYC amplification (2)
HR positive + MYC amplification (2)
MYC amplification + ALK F1174L (2)
MYC expression + MYC rearrangement (2)
MYC overexpression + IDH1 mutation (2)
MYC overexpression + IDH2 mutation (2)
MYC rearrangement + LDH elevation (2)
BCL2/MCL1 ratio elevation (2)
ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)
ALK positive + MYC amplification + CCND1 deletion (1)
EGFR T790M + MYC amplification (1)
HER-2 positive + MYC amplification (1)
HR positive + MYC mutation (1)
IDH1 mutation + MYC amplification + MAPRE1 overexpression (1)
IDH2 mutation + MYC amplification + MAPRE1 overexpression (1)
KIF5B-RET fusion + TP53 H193R + MYC amplification (1)
MYC amplification + BCL2 amplification + TNFRSF8 expression (1)
MYC mutation + ER positive (1)
miR-17-HG deletion + MYC positive (1)
BCL2 elevation + IGH elevation (1)
BCL2 fusion + EZH2 mutation (1)
Chr t(11;14) + BCL2 : BCL2L1 ratio elevation (1)
Chr t(11;14) + BCL2 overexpression (1)
PTEN deletion + BCL2 translocation (1)
BCL2/BAX ratio elevation (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
chidamide
Sensitive: A1 - Approval
chidamide
Sensitive
:
A1
chidamide
Sensitive: A1 - Approval
chidamide
Sensitive
:
A1
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
methotrexate
Resistant: C3 – Early Trials
methotrexate
Resistant
:
C3
methotrexate
Resistant: C3 – Early Trials
methotrexate
Resistant
:
C3
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
cytarabine + methotrexate
Resistant: C3 – Early Trials
cytarabine + methotrexate
Resistant
:
C3
cytarabine + methotrexate
Resistant: C3 – Early Trials
cytarabine + methotrexate
Resistant
:
C3
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
Resistant: C3 – Early Trials
Resistant
:
C3
Resistant: C3 – Early Trials
Resistant
:
C3
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
lenalidomide + zanubrutinib
Sensitive: C3 – Early Trials
lenalidomide + zanubrutinib
Sensitive
:
C3
lenalidomide + zanubrutinib
Sensitive: C3 – Early Trials
lenalidomide + zanubrutinib
Sensitive
:
C3
BCL2 expression + MYC expression
Lymphoma
BCL2 expression + MYC expression
Lymphoma
methotrexate
Resistant: C3 – Early Trials
methotrexate
Resistant
:
C3
methotrexate
Resistant: C3 – Early Trials
methotrexate
Resistant
:
C3
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
orelabrutinib
Sensitive: C3 – Early Trials
orelabrutinib
Sensitive
:
C3
orelabrutinib
Sensitive: C3 – Early Trials
orelabrutinib
Sensitive
:
C3
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
CD20-targeted CAR-T immunotherapy + venetoclax
Sensitive: D – Preclinical
CD20-targeted CAR-T immunotherapy + venetoclax
Sensitive
:
D
CD20-targeted CAR-T immunotherapy + venetoclax
Sensitive: D – Preclinical
CD20-targeted CAR-T immunotherapy + venetoclax
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login